Sino Biopharmaceutical Reports Promising Lung Cancer Study Results

Sino Biopharmaceutical (HK:1177) has released an update.

Sino Biopharmaceutical has announced positive results from its Phase III study of Benmelstobart Injection combined with chemotherapy, followed by Anlotinib Hydrochloride Capsules as a first-line treatment for advanced squamous non-small cell lung cancer. The interim analysis showed significant improvement in progression-free survival compared to the existing treatment, marking a promising development for patients with this challenging cancer subtype. The company plans to submit a marketing application for this new indication soon, which could offer new hope for cancer treatment.

For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.